BPC-157 vs GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
BPC-157 (Synthetic pentadecapeptide) and GLOW Blend (BPC-157 + TB-500 + GHK-Cu) (Multi-component research blend) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | BPC-157 | GLOW Blend (BPC-157 + TB-500 + GHK-Cu) |
|---|---|---|
| Compound class | Synthetic pentadecapeptide | Multi-component research blend |
| Research category | Healing & Recovery | Cosmetic & Dermal |
| Length (amino acids) | 15 amino acids | Not documented |
| Molecular weight | 1419.5 Da | Not documented |
| Half-life | <30 minutes (elimination, reported in rats/dogs) | Not documented |
| Origin | BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research. | GLOW is a marketed research blend combining BPC-157, TB-500, and GHK-Cu. It is not a naturally occurring substance and exists only as a formulated combination whose exact composition may vary by supplier. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How BPC-157 works
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
How GLOW Blend (BPC-157 + TB-500 + GHK-Cu) works
As a blend, GLOW combines the documented properties of its components: BPC-157's angiogenesis and growth-factor-related repair signaling, TB-500's actin regulation and cell-migration activity, and GHK-Cu's copper-delivery and extracellular-matrix remodeling signaling. These properties derive from separate preclinical and cosmetic research; the combined formulation itself is not validated in controlled human trials.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
BPC-157
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
What sets each apart
BPC-157
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
GLOW is oriented toward combined skin and tissue-repair research, adding the copper tripeptide GHK-Cu to the BPC-157/TB-500 pairing found in simpler blends.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
What is the GLOW blend?
The GLOW blend is a research-peptide combination of BPC-157, TB-500, and GHK-Cu. Each component targets a different aspect of tissue and skin remodeling, and the blend is studied together rather than as a single approved drug.
What does each component contribute?
In research framing, BPC-157 is associated with angiogenesis (new blood-vessel growth) at injury sites, TB-500 with actin regulation and migration of repair cells, and GHK-Cu with copper delivery and collagen/elastin matrix remodeling. The rationale is complementary, non-overlapping mechanisms.
What ratio is the GLOW blend usually sold in?
Many GLOW research products are pre-blended in a 5:1:1 ratio of GHK-Cu to TB-500 to BPC-157 (for example 50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157 per vial). Ratios vary by supplier, so the certificate of analysis should be checked for the exact amounts.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.